These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1834602)

  • 1. Cost-benefit analysis of hepatitis-B vaccination. A computerized decision model for Spain.
    Jönsson B; Horisberger B; Bruguera M; Matter L
    Int J Technol Assess Health Care; 1991; 7(3):379-402. PubMed ID: 1834602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of hepatitis-B vaccine in Greece. A country of intermediate HBV endemicity.
    Hatziandreu EJ; Hatzakis A; Hatziyannis S; Kane MA; Weinstein MC
    Int J Technol Assess Health Care; 1991; 7(3):256-62. PubMed ID: 1834601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness.
    Stephenne J
    Vaccine; 1988 Aug; 6(4):299-303. PubMed ID: 2973187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela].
    Fernández Barboza R; Rivero D; Echeverría B; Machado IV
    Bol Oficina Sanit Panam; 1991 Jul; 111(1):16-23. PubMed ID: 1834080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.
    Antoñanzas F; Garuz R; Rovira J; Antón F; Trinxet C; Navas E; Salleras L
    Pharmacoeconomics; 1995 May; 7(5):428-43. PubMed ID: 10155330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of universal vaccination against hepatitis B virus.
    Fenn P; Gray A; McGuire A
    J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.
    Levaux HP; Schonfeld WH; Pellissier JM; Cassidy WM; Sheriff SK; Fitzsimon C
    Pediatrics; 2001 Aug; 108(2):317-25. PubMed ID: 11483794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY; Billah K; Lieu TA; Weinstein MC
    Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A method for evaluating the hepatitis B vaccination program].
    Corrao G; Calleri M; Carle F; Russo R; Favilli S
    Ann Ist Super Sanita; 1989; 25(2):337-43. PubMed ID: 2531564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A cost-effectiveness analysis of vaccination against the hepatitis B virus].
    Antoñanzas F; Forcén T; Garuz R
    Med Clin (Barc); 1992 Jun; 99(2):41-6. PubMed ID: 1630178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
    Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of hepatitis A and B vaccination programme in Germany.
    Szucs T
    Vaccine; 2000 Feb; 18 Suppl 1():S86-9. PubMed ID: 10683559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The costs of hepatitis B vaccination: a re-evaluation].
    van de Ven AA; van Hattum J; Willers JM
    Ned Tijdschr Geneeskd; 1990 Feb; 134(6):298-301. PubMed ID: 2137560
    [No Abstract]   [Full Text] [Related]  

  • 15. An economic assessment of pre-vaccination screening for hepatitis A and B.
    Jacobs RJ; Saab S; Meyerhoff AS; Koff RS
    Public Health Rep; 2003; 118(6):550-8. PubMed ID: 14563912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese strategies for hepatitis B virus markers screening in hepatitis B vaccination based on cost-effectiveness analysis].
    Zhang SX
    Zhonghua Yu Fang Yi Xue Za Zhi; 1992 May; 26(3):154-8. PubMed ID: 1395956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Forecasting strategies of hepatitis B vaccination based on decision tree model].
    Zhang SX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Aug; 10(4):193-7. PubMed ID: 2509074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of intradermal vs. subcutaneous hepatitis B vaccination for the mentally handicapped.
    Hayashi J; Nakashima K; Noguchi A; Morofuji M; Kashiwagi S
    J Infect; 1991 Jul; 23(1):39-45. PubMed ID: 1832182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
    Harris A; Yong K; Kermode M
    Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.